According to an NBC News article, an FDA panel rejected Biogen’s experimental Alzheimer’s drug due to a lack of “strong evidence” it works. The drug is aducanumab, and it has received ample criticism after experts identified “red flags” in the data, which didn’t show any initial benefits.
FDA Panel Rejects New Alzheimer’s Drug
Biogen’s experimental Alzheimer’s drug lacks enough evidence for FDA approval.
Nov 11, 2020
Sustainable Healthcare Packaging Solutions That Work
Industry leaders share proven strategies for reducing packaging emissions by up to 70% while meeting safety and regulatory requirements.
Read More
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
Downloads
